Based on the multifaceted findings mentioned above, we have elucidated the oncogenic potential of MVP in driving tumorigenesis of PAAD and its feasibility as a biomarker for clinical diagnosis and prognosis of PAAD. This evidence concerns the gene MVP and pancreatic adenocarcinoma.